On 13 September 2013, CGPDTM launched the
Dynamic Utility interface to view the disposal status of various patent
applications spanning respective technology examination groups. The dynamic
real time display illustrates well assorted panels like month and year
selection. The display also categorizes patent applications under various
technology examination groups i.e. Electronics, Mechanical, Chemical and
Biotechnology respectively. The number of patent applications Granted, Refused
and Abandoned u/s 21(1) for the specific patent office, month and year can be
accessed via the interface. For details click here.
A blog discussing the current buzz in the global IP scenario to keep you updated.
Saturday, September 14, 2013
Monday, July 8, 2013
Madrid Protocol: Indian entry
As per the latest notification on the IPO website, the
provisions related to the registration of International Trade Marks under
Madrid Protocol came into force on 8th July 2013. Additionally, the
provisions of the Trademarks Amendment
Rules (2013) came into effect on the very same day. Notification can be
accessed here.
( Image Courtesy link )
Labels:
Madrid Protocol
Wednesday, June 5, 2013
Trendspotting Intellectual Property
We often see firms concentrating
on trendspotting the latest business fads and replicating popular innovations. Amidst
this it is equally crucial to eye on spotting the latest intellectual property
trends. “Licensing Out“ the patented technology is one such trend that has been
there for quite some time. Building a fruitful licensing program shall fall into the
“to do’s” list of all technology oriented firms. Regular check on updates, review and
assessment of agreements, terms and conditions can shape up a licensing program
to ensure better revenues and capture the essence of inherent Intellectual
Property value of the assets.
Another popular course is the IP
portfolio sale. In the recent times , patent sales have been one such phenomenon
that garnered the headlines. Whether it’s Kodak’s Digital Imaging patents sale,
Nortel’s telecommunication patent
portfolio sale or Motorola Mobility’s mobile and wireless patents sale, all
these firms have managed to generate appreciable revenues from their underlying
IP assets.
Patent Pooling is another such IP
trend where companies agree to cross-license their patents in a consortium
called patent pool. The prime vantage is the fact that you stop counter suing
each other! On a more serious note, Patent pooling is one potent IP strategy in
today’s competitive technology scenario where patents tend to have overlapping
and interconnected patent claims. Expensive litigation and costly follow ups
can strain the financial backbone of many firms. Patent pools, thus offer a
strategic solution in the light of abovementioned issues.
IP Mortgaging is another strategy
on the block. Patentees may use their patents, trademarks and
designs as a security or collateral for potential loans. Thus, maximizing the benefits
of their inherent IP assets. Trendspotting not only cast insights on the
current IP practices but also lay foundation of a strong IP program for your
organization. We hope the current
intellectual property trends continue to foster innovation, security and most
importantly the growth of IP assets.
(Image courtesy link)
(Image courtesy link)
Saturday, March 2, 2013
Patent thickets: Do we need white spacing
Intellectual Property rights play
a crucial role in the holistic development and protection of IP assets of your
organization. For a brief moment think about the umpteen patents filed within a
year under software or mobile technology domain. Definitely the count is high
and likewise is the case for other booming technology wizards. The race for
securing a patent starts from the very stage when an idea is conceived and goes
on till you secure one. Eventually this leads to the ever-growing and
overlapping, dense web of technology patent rights, also termed as Patent thickets. If your Tech organization is planning for securing patents, make sure
you successfully pave your way through this dense cloud to commercialize your potent
technology.
There have been many debates
across the IP community on Patent thickets contributing to technological complexities
and acting as innovation barriers. The need of the hour is to Whitespace the
patent landscape and spot the potential areas of interest. Whitespacing will
result in recognizing technology areas with little or lacking patent
activities thereby lending you an exclusivity in the global marketplace. Patent
Whitespace analysis could be a potential remedy for patent thickets and
innovation black holes. Thus, organizations
shall enforce resultant patent whitespace data for R&D and overall
innovation. We hope this approach holds
promise to pave your organization's way through patent thickets.
(Image Courtesy Link)
Monday, January 7, 2013
ALIMTA's Patent: A stronger foothold?
Pharmaceutical patents have
always been in the limelight worldwide. While the drug manufacturers face a
stiff competition from the ever-expanding generics market, acquiring timely
patents on new drugs ensure firm market foothold and pose potential barriers to
entry. The much talked about Eli Lilly’s lung cancer
drug patent on ALIMTA set to expire in 2016 , raising questions on the
overall market sales and stringent competition from the generics drug market
thereafter. But thanks to ALIMTA’S “method
of use patent” (popularly known as '209 patent) aimed at the method of administering
antifolate to mammals.
Even though the basic patent on the lung
cancer drug ALIMTA is about to expire in the year 2016, Eli Lilly’s latter
patent ('209) which is set to expire
by the end of 2021 could potentially keep ALIMTA’s generics on hold. Reason
being the very fact that '209 patent
covers the specific method of administering the lung cancer drug ALIMTA and its
dosage procedure which apparently happens to be mentioned on the drug’s label
as well. Eli’s attempt to safeguard its popular drug by "method of use" based supporting patent ‘209 could prove to be a
smarter move when annual sales of ALIMTA are expected to rise to $3.5 billion by 2016.
On the other hand defendants and
generic drug manufacturers tend to legally argue the validity of the ‘209 patent.
Details can be accesses here. Recently many Pharmaceutical giants faced massive
competition from the generic drug industry upon patent expiry thereby leading
to slashed sales and overall revenues. Eli’s efforts to protect its basic drug
patent with supporting “method of use" based patents could potentially hit the bull’s eye
and possibly initiate a trend of such supporting patents.
(Image courtesy link)
Subscribe to:
Posts (Atom)